Shock Syndromes II

Madsen TE, Simmons J, Choo EK, Portelli D, McGregor

AJ, Napoli AM. The DISPARITY study: do gender dif-

ferences exist in Surviving Sepsis Campaign resuscitation

bundle completion, completion of individual bundle ele-

e7-11. https://doi.org/10.1016/j.jcrc.2014.01.002

McKinley BA, Kozar RA, Cocanour CS, et al.

Normal

versus

supranormal

oxygen

delivery

goals in shock resuscitation: the response is the

same. J Trauma. 2002;53(5):825-832. https://doi.

org/10.1097/00005373-200211000-00004

Meizoso JP, Dudaryk R, Mulder MB, et al. Increased risk

of fibrinolysis shutdown among severely injured trauma

patients receiving tranexamic acid. J Trauma Acute

Care Surg. 2018;84(3):426-432. https://doi.org/10.1097/

ta.0000000000001792

Milling TJ Jr, Refaai MA, Sarode R, et al. Safety of a

four-factor prothrombin complex concentrate versus

plasma for vitamin k antagonist reversal: an integrated

analysis of two phase IIIb clinical trials. Acad Emerg

Med.

2016;23(4):466-475.

https://doi.org/10.1111/

acem.12911

Moore HB, Moore EE, Chapman MP, et al. Plasma-

first resuscitation to treat haemorrhagic shock during

emergency ground transportation in an urban area: a

https://doi.org/10.1016/s0140-6736(18)31553-8

Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter

MJ, Rasmussen TE. Association of cryoprecipitate

and tranexamic acid with improved survival following

wartime injury: findings from the MATTERs II study.

jamasurg.2013.764

Murphy GJ, Pike K, Rogers CA, et al. Liberal or

restrictive transfusion after cardiac surgery. N Engl J

Med. 2015;372(11):997-1008. https://doi.org/10.1056/

nejmoa1403612

Myles PS, Smith JA, Forbes A, et al. Tranexamic acid

in patients undergoing coronary-artery surgery. N Engl

J Med. 2017;376(2):136-148. https://doi.org/10.1056/

nejmoa1606424

Neal MD, Hoffman MK, Cuschieri J, et al. Crystalloid

to packed red blood cell transfusion ratio in the mas-

sively transfused patient: when a little goes a long way.

J Trauma Acute Care Surg. 2012;72(4):892-898. https://

doi.org/10.1097/ta.0b013e31823d84a7

Nutescu EA, Dager WE, Kalus JS, et al. Management of

bleeding and reversal strategies fo r o r a l a n t i c o a g-

u l a n t s: cl i n i c a l p r a c t i c e c o n s i d e r a t i o n s .

org/10.2146/ajhp130243

O’Shea RS, Davitkov P, Ko CW, et al. AGA clinical prac-

tice guideline on the management of coagulation disorders in

patients with cirrhosis. Gastroenterology. 2021;161(5):1615-

1627.e1. https://doi.org/10.1053/j.gastro.2021.08.015

Panteli M, Pountos I, Giannoudis PV. Pharmacological

adjuncts to stop bleeding: options and effectiveness. Eur

J Trauma Emerg Surg. 2016;42(3):303-310. https://doi.

org/10.1007/s00068-015-0613-x

Peltan ID, Vande Vusse LK, Maier RV, Watkins TR.

An international normalized ratio-based definition of

acute traumatic coagulopathy is associated with mor-

tality, venous thromboembolism, and multiple organ

1438. https://doi.org/10.1097/ccm.0000000000000981

Pham TN, Cancio LC, Gibran NS; American Burn

Association. American Burn Association practice

guidelines burn shock resuscitation. J Burn Care

Res.

2008;29(1):257-266.

https://doi.org/10.1097/

bcr.0b013e31815f3876

Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab

for dabigatran reversal—full cohort analysis. N Engl

J Med. 2017;377(5):431-441. https://doi.org/10.1056/

nejmoa1707278

Porter JM, Ivatury RR. In search of the optimal

end points of resuscitation in trauma patients: a

review. J Trauma. 1998;44(5):908-914. https://doi.

org/10.1097/00005373-199805000-00028

Prochaska M, Salcedo J, Berry G, Meltzer D. Racial

differences in red blood cell transfusion in hospitalized

patients with anemia. Transfusion. 2022;62(8):1519-

1526. https://doi.org/10.1111/trf.16935

Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and

safety of a 4-factor prothrombin complex concentrate in

patients on vitamin K antagonists presenting with major

bleeding: a randomized, plasma-controlled, phase IIIb

study. Circulation. 2013;128(11):1234-1243. https://doi.

org/10.1161/circulationaha.113.002283

Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet

alfa for the reversal of factor Xa inhibitor activity. N Engl

J Med. 2015;373(25):2413-2424. https://doi.org/10.1056/

nejmoa1510991